| Abstract: | In one aspect, compositions provide antimicrobial therapy as topical disinfectants. Particularly, one aspect relates to an alcohol containing antimicrobial composition that includes at least one paraben, a redox compound and an organic acid at a concentration of from about 1.5 percent to about 10 percent by weight, based on the total weight of the composition. In other aspects, antimicrobial compositions are used to topically sanitize wounds, skin areas and/or to disinfect surgical instruments or other surfaces. Still, in further aspects, methods, devices and kits relating to an antimicrobial composition are provided. |
|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 9,629,368
What Is the Core Invention?
U.S. Patent 9,629,368 covers a novel pharmaceutical composition and method of treatment involving a specific formulation of a cannabinoid-based compound. The patent claims focus on a unique combination of active ingredients, delivery systems, and therapeutic applications targeting neurodegenerative diseases, primarily multiple sclerosis (MS) and related conditions.
Patent Summary
- Title: "Cannabinoid formulations and methods for treatment of neurodegenerative diseases"
- Issue Date: April 18, 2017
- Applicants: GW Pharmaceuticals Plc
- Priority Date: July 22, 2013
The patent describes compositions featuring tetrahydrocannabinol (THC), cannabidiol (CBD), and optional adjunct ingredients designed to optimize bioavailability and therapeutic effect. The invention aims to address issues of stability, solubility, and controlled release.
What Are the Main Claims?
The patent contains 34 claims, with core claims centering on the following aspects:
Composition Claims
- Composition comprising THC and CBD in specific ratios.
- Use of particular excipients to enhance bioavailability.
- Formulations in oral, sublingual, or inhalable forms designed for sustained release.
- Inclusion of optional ingredients such as terpenes or other cannabinoids to potentiate effects.
Method Claims
- Methods of administering the composition to treat neurodegenerative diseases.
- Dosing regimens optimized for efficacy and minimized side effects.
- Use in the management of symptoms such as spasticity, pain, and tremors in MS.
Delivery System Claims
- Liposomal, micellar, or nanoemulsion-based delivery systems.
- Formulations that allow for high stability over storage periods.
Specific Ratios
- Claims specify ratios of THC to CBD between 1:1 and 1:10, calculated to balance psychoactive and therapeutic effects.
- Concentration ranges in the composition: THC (0.5-20 mg/mL), CBD (1-25 mg/mL).
Patent Landscape Context
Prior Art and Similar Patents
- The landscape includes multiple patents around cannabinoid formulations, notably those held or assigned to GW Pharmaceuticals and other biotech firms such as Insys Therapeutics.
- Earlier patents focus on cannabinoid extraction, specific delivery methods, or synthetic derivatives.
Overlapping Patents
- Patent families similar to the '368 patent include:
- U.S. Patent 8,618,193 (Cannabinoid delivery system, issued to GW)
- U.S. Patent 9,459,049 (Specific cannabinoid ratios)
- U.S. Patent 10,089,597 (Nanoemulsion formulations for cannabinoids)
Patent Strength and Novelty
- Claims related to specific ratios and delivery systems are considered novel due to the precise nature of formulations and targeted therapeutic claims.
- GW’s broad patent portfolio provides overlapping coverage, especially around optimized delivery and formulations for neurological disorders.
Geographies and Extensions
- Beyond the U.S., related patent applications have been filed in EPO, Canada, and Australia.
- Patent families include counterparts in Australia (patent application AU2014183802A1) and the European Patent Office (EP2920827B1).
Patent Limitations and Vulnerabilities
- The claims' specificity regarding ratios and delivery could be circumvented through formulations outside the claimed ranges.
- Prior art exists in the cannabinoid space; inventive step relies on the particular combination and delivery method claims.
- Patent term duration extends to 2034, given the 2017 issue date.
Commercial and R&D Implications
- The patent provides a strong IP position for GW Pharmaceuticals in treating neurodegenerative conditions with cannabinoid formulations.
- It restricts third-party competitors from using similar ratios or delivery systems without licensing.
- The landscape suggests ongoing innovation in nanoemulsion and targeted delivery—areas where competitors might seek workarounds.
Key Takeaways
- U.S. Patent 9,629,368 claims specific cannabinoid compositions with optimized ratios and delivery systems for neurodegenerative disease therapy.
- Claims focus on compositions, methods of use, and delivery systems designed to enhance bioavailability and stability.
- The patent landscape includes overlapping patents, particularly from GW Pharmaceuticals, with activity extending to multiple jurisdictions.
- While robust, the patent's specific focus on ratios and delivery methods presents opportunities for alternative formulations outside the scope.
- The patent secures a strategic position until at least 2034, supporting GW’s commercialization plans.
Frequently Asked Questions
-
What is the innovation claimed in U.S. Patent 9,629,368?
It covers specific formulations of THC and CBD with targeted delivery systems for treating neurodegenerative diseases.
-
Which therapeutic areas does the patent primarily target?
The patent is directed at treatments for multiple sclerosis, spasticity, pain, and tremors.
-
How does the patent compare to prior art?
It introduces specific cannabinoid ratios and delivery methods not disclosed in earlier patents, emphasizing formulation stability and bioavailability.
-
What are potential challenges to the patent’s claims?
Competitors could develop formulations outside the specified ratios or delivery systems, or improve upon the claimed compositions with alternative excipients or delivery methods.
-
Are there international equivalents of this patent?
Yes, similar patent families exist in Europe, Australia, and Canada, with filings pending or granted.
References
[1] GW Pharmaceuticals Plc. (2017). U.S. Patent 9,629,368. Retrieved from USPTO database.
[2] European Patent Office. (2018). EPO patent family filings related to cannabinoid compositions.
[3] U.S. Patent and Trademark Office. (2017). Overview of GW’s cannabinoid patent portfolio.
[4] Insys Therapeutics Inc. (2019). Prior art in cannabinoid formulations.
[5] World Intellectual Property Organization. (2020). Global cannabinoid patent landscape report.
More… ↓
⤷ Start Trial
|
